VOLUNTARY ANNOUNCEMENT - ENTER INTO PARTNERSHIP WITH BOEHRINGER INGELHEIM WITH POTENTIAL TOTAL DEAL VALUE OF US$7 BILLION

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2026

VOLUNTARY ANNOUNCEMENT - TQ-A3334 “TLR7 AGONIST” AND TQA3605 “CORE PROTEIN ALLOSTERIC MODULATOR” GRANTED BREAKTHROUGH THERAPY DESIGNATION BY CDE

VOLUNTARY ANNOUNCEMENT - DATA FROM TWO CLINICAL STUDIES OF TQB2102 “HER2 BIPARATOPIC ADC” PRESENTED AT 2026 ESMO

NEXT DAY DISCLOSURE RETURN

VOLUNTARY ANNOUNCEMENT - COMPLETION OF ALL PARTICIPANTS ENROLLMENT IN THE PHASE III REGISTRATIONAL CLINICAL TRIAL OF TQC2731 INJECTION “TSLP MONOCLONAL ANTIBODY” FOR CHRONIC SINUSITIS WITH NASAL POLYPS

VOLUNTARY ANNOUNCEMENT - LATEST RESEARCH RESULTS ON TQ-A3334 “TLR7 AGONIST” AND BEPIROVIRSEN “ASO” TO BE PRESENTED AT 2026 AASLD

NEXT DAY DISCLOSURE RETURN